X

Trial Profile

A phase I/II study of Pazopanib and weekly Topotecan in patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Aug 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary) ; Topotecan (Primary)
Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; Biomarker; Therapeutic Use
Acronyms TOPAZ

Most Recent Events

01 Aug 2023 Results (n=61) assessing safety and efficacy of the combination of Topotecan with Pazopanib in platinum-resistant or intermediate-sensitive recurrent ovarian cancer published in the Journal of Cancer Research and Clinical Oncology
26 Sep 2018 This trial has been completed in Germany.
05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com